Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.

Acute Myeloid Leukemia Core-Binding Factor Gemtuzumab Ozogamicin Intensive Chemotherapy

Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 21 11 2023
revised: 23 01 2024
accepted: 24 02 2024
medline: 10 3 2024
pubmed: 10 3 2024
entrez: 9 3 2024
Statut: aheadofprint

Résumé

In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center retrospective analysis to compare outcomes of patients with CBF-AML treated with intensive induction chemotherapy, with or without a single dose of GO 3 mg/m

Identifiants

DOI: 10.1016/j.leukres.2024.107467 PMID: 38460432
pubmed: 38460432
pii: S0145-2126(24)00033-X
doi: 10.1016/j.leukres.2024.107467
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107467

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no relevant conflict of interest.

Auteurs

Garrett Bourne (G)

Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Kendall Diebold (K)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Manuel Espinoza-Gutarra (M)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Zaid Al-Kadhimi (Z)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Kimo Bachiashvili (K)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Sravanti Rangaraju (S)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Pankit Vachhani (P)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Ravi Bhatia (R)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Omer Jamy (O)

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: omerjamy@gmail.com.

Classifications MeSH